Keytruda (pembrolizumab)
pCPA File Number:
23081
Negotiation Status:
Concluded with an LOI
Indication(s):
For the treatment of adult patients with resectable Stage II, IIIA, or IIIB (T3-4N2) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery.
Sponsor/Manufacturer:
Merck Canada Inc.
CDA-AMC Project Number:
PC0385-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded: